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Abstract 
 
 The dopamine (DA) transporter (DAT) is a sodium symporter (NSS) transporter protein 
that removes dopamine from the synaptic cleft to the pre-synaptic nerve terminal.  This DAT 
function regulates dopaminergic signaling and controls brain functions such as motor control, 
behavior, and learning. DAT is regulated by signal and protein cascade pathways, and thus is 
trafficked to and from the nerve terminal cell surface to modulate DA uptake.  This project 
investigates the role of calmodulin (CaM) in the signaling pathway affecting DAT trafficking, 
and specifically focuses on whether CaM is required for PKC-mediated DAT surface expression.  
DA transport assays conducted in the presence of a CaM inhibitor, CGS 9343B, revealed a trend 
toward CaM’s ability to increase DAT function, although no conclusive results were established 
due to time constraints.  Preliminary results suggest that CaM is able to increase DAT function, 
but whether it affects DAT surface levels is the foundation for further investigations. 
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Background 
 
Dopamine 
Dopamine (3,4-dihydroxyphenethylamine) (DA) is a catecholamine neurotransmitter, 
named after the similarly structured molecular precursor L-DOPA, distinguished by the removal 
of a carboxyl group from the nitrogen bound carbon.  Dopamine is derived from the amino acid 
tyrosine and is a precursor to the monoamines norepinephrine and epinephrine 
(GHR.NLM.NIH.gov, 2014).  Two scientists considered the pioneers of DA research, Arvid 
Carlsson and Paul Greengard, were awarded the Nobel Prize in Physiology and Medicine in 
2000 for their basic research on DA.  Arvid Carlsson discovered DA as a neurotransmitter in the 
brain approximately 60 years ago using the brains of reserpinized animals treated with L-DOPA 
along with the then-recent technology of spetrophotofluorimetry. Using this discovery, Carlsson 
was able to map regional distributions of DA, and show where the highest concentrations were 
located (nobelprize.org, 2014).   
 
Dopamine Pathways 
 Dopamine is found in its highest concentrations in the basal ganglia and substantia nigra 
regions of the midbrain (Cheramy et al., 1981; Cheramy et al., 1988).  Using fluorescence 
histochemical methods, three major trajectories (pathways) of DA neurons have been outlined 
from the dopaminergic neurons of the midbrain to the: dorsal striatum, ventral striatum including 
the nucleus accumbens, and prefrontal cortex (Ungerstedt, 1976; Moore and Bloom, 1978).  
Projecting from the substantia nigra to the striatum, the nigro–striatal pathway is one of the main 
dopaminergic projections involved in simple or complex, conditioned or unconditioned motor 
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behaviors (Barnes et al., 2005).  An important feature of this pathway is that it has been 
elucidated to contain coordinated, multiple, parallel, and recurrent anatomical loops which link 
the midbrain, basal ganglia, thalamus, and cortex with respect to motor behavior (Haber, 2003; 
Alexander et al., 1990).  The use of dopamine grafts by Döbrössy and Dunnett (2001) showed 
the organization of the dorsal striatal area and the cortex to be vital areas for the development 
and learning of complex motor behavior in rats.  Upon the initial realization that the nucleus 
accumbens has a strong relation to the limbic system (Heimer et al., 1997), it was proposed that 
mesolimbic dopamine pathways could have an important role in motivation, specifically between 
certain actions and their produced outcomes (Mogenson et al., 1980).  Projections to the ventral 
striatum are significant for goal-directed behavior-based learning and reinforcement.  This is 
based on the animal’s learned ability to predict outcomes based on their actions and the value of 
these outcomes, which has been termed the “cognitive value system” (Dickinson and Balleine, 
1994).  In addition, Balleine and Dickinson (1991) named another value system, the “pleasure 
system”, as a result of the proposed hypothesis of the role of ventral striatal dopaminergic 
pathways in reward prediction.  Dopamine input to the nucleus accumbens core has been shown 
in a recent study to possess information about the salience of perceived objects, defined as a 
certain quality that makes them memorable in order to facilitate learning (Kapur, 2004).  At a 
functional level, increases in DA release into the synapse and phasic bursts of DA neurons firing 
have been proposed as signals at postsynaptic neurons that is relevant to promoting reward 
prediction or incentive salience (Waelti et al., 2001).  Kapur (2004) postulated that abnormal 
function of this type of neuronal firing and synaptic release of DA could cause psychotic 
delusions in schizophrenic patients.  The accumbens shell possesses the control of DA input to a 
variety of areas in the striatum as a result of differences in neuronal pattern organization and 
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efferent targets, which is thought to stimulate behaviors between the accumbens core and dorsal 
striatum (Zabrokszky et al., 1985; Usuda et al., 1998; Voorn et al., 1989).  The mesolimbic DA 
neurons transmit DA from the ventral tegmental area (VTA) to the limbic system through the 
nucleus accumbens, and is thought to be essential for associative learning.  The disruption of this 
pathway is speculated to potentially enhance some of the negative effects of schizophrenia and 
ADHD (Rosenkranz and Grace, 2002).  Finally, the mesocorticol pathway contains mostly D1 
type DA receptors which are modulators of cognitive behavior and spatial working memory 
(Desimone, 1995).  D2 DA receptors are also present, in fewer numbers, but have been found to 
correlate with quick movements, or saccades, that are memory guided (Wang et al., 2004). 
 
Dopamine Diseases 
 Since DA is involved in a variety of brain functions including reward, motor control, and 
learning, it is reasonable to speculate that any variance in normal DA function can lead to 
diseases in the nervous system.  Three well documented diseases associated with DA dysfunction 
are Parkinson’s, schizophrenia, and attention deficit hyperactivity disorder (ADHD).  
Parkinson’s is a motor system disorder than generally develops in people over the age of 50.  It is 
caused by a rapid loss of dopamine-producing brain cells in the substantia nigra, in addition to 
depleted levels of dopamine in the basal ganglia, which cause symptoms like tremors, rigidity, 
and increased difficulty in starting movements/tasks.  The DA precursor L-DOPA has been given 
as a treatment to increase levels of DA, and is now combined with other drugs to prevent L-
DOPA metabolism (NINDS.NIH.gov, 2014).  Schizophrenia is a severely chronic and crippling 
brain disorder that generates delusional ideas and sounds (voices) in the minds of the affected.  
The causes of this disease are unknown, but are speculated to be a result of a multitude of factors 
  
 
8 
such as genes (passed from previous generations predisposed to the disorder) and differences in 
brain chemistry and structure (imbalances in intertwined chemical reactions involving DA and 
possibly other neurotransmitters) (NIH.gov Schizophrenia, 2014).  ADHD is a disorder that 
causes difficulty in paying attention to tasks at hand, hyperactivity, and controlling one’s 
behavior.  The neurological basis of this disorder is currently a subject of research and debate, 
although some of the prospective reasons include genes, environmental factors, brain injuries, 
nutrition, and social environments (NIH.gov ADHD, 2014).  Psychostimulants are commonly 
used to treat symptoms of this disorder such as Ritalin and Adderal (amphetamine), which act on 
the dopamine transporter (DAT) to have an end effect of increasing synaptic levels of dopamine 
(Iversen, 2006). 
 
Dopamine Transporter (DAT) 
The dopamine transporter (DAT) is a monoamine neurotransmitter transporter that 
belongs to the sodium symporters (NSS) family, also termed the solute carrier 6 (SLC6) family.  
The family includes the norepinephrine, serotonin, glycine, and GABA (gamma-aminobutyric 
acid) transporters.  Around five decades ago, Julius Axelrod discovered monoamine reuptake in 
sympathetic nerve terminals, which he proposed was an essential process for the termination of 
released neurotransmitters (Hertting and Axelrod, 1961).  Soon after, the mechanisms for 
dopamine uptake were elucidated, and were similar but distinct from noradrenaline (Iversen, 
1971), and lead to the realized importance of monoamine reuptake and functional properties of 
these pre-synaptic sites.  DAT, a 620 residue protein, exists as a polytopic membrane protein 
containing twelve transmembrane domains (TMDs) with both amino (N) and carboxy (C) 
termini residing in the cytoplasm of the cell (Bruss et al., 1995; Hersch et al., 1997; Chen et al., 
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1998; Androutsellis-Theotokis and Rudnick, 2002).  The N and C termini of mammalian NSS 
proteins are highly conserved among species, but are not well conserved between different types 
of NSS transporters.  This differing conservation pattern is observed to play a role in regulation 
of specific, targeted transporters within a cell through protein-protein interactions or post-
translational modifications (Eriksen et al., 2010).  A high resolution crystal structure of LeuT, a 
bacterial homologue of mammalian NSS proteins, was used to confirm the DAT structure 
(Yamashita et al., 2005) and eventually led to further studies showing that NSS proteins are 
oligomeric assemblies in the plasma membrane (Sitte et al., 2004).  The actual crystal structure 
of Drosophila DAT was revealed in 2013 (Penmatsa et al., 2013) and was an important 
breakthrough in the field of neuroscience.  Although the actual role of oligomerization has not 
been fully clarified, it has been proposed by Torres et al. (2003) to play a part in DAT trafficking 
to the cell surface.  For DAT specifically, the transporter protein dimerizes from symmetrical 
crosslinking of cysteine residues located on the sixth TMD’s extracellular face (Hastrup et al., 
2001).   
DAT is located in the same regions of the brain where DA is secreted in high 
concentrations, such as the substantia nigra, the ventral tegmental area (VTA), and the basal 
ganglia (Hoffman et al., 1998).  Immunoreactivity experiments have shown projections of 
dopaminergic neurons to the: striatum, nucleus accumbens, olfactory tubercle, nigrostriatal 
bundle, lateral habenula, and prefrontal cortex (Hersch et al., 1997; Freed et al., 1995; Ciliax et 
al., 1995).  These dopaminergic neurons occupy many regions of the brain in subpopulations of 
the midbrain where their protein expression levels and projections distinguish them from one 
another (Greene, 2006; Lammel et al., 2008).  Interestingly enough, DAT is also found in regions 
outside of the brain such as the stomach, pancreas, and kidney (Eisenhofer, 2001).   
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 Localized on the pre-synaptic plasma membrane nerve terminals of dopaminergic 
neurons, DAT regulates the uptake of dopamine from the synapse into the pre-synaptic neuron.  
This allows DAT to regulate signaling from dopaminergic neurons and to mediate how much 
extracellular dopamine is maintained (reviewed in Eriksen et al., 2010).  SCAM (substituted 
cysteine accessibility method) analysis suggested a role of the third extracellular loop of DAT to 
be a vital element in the translocation pathway of binding substrates, for DA reuptake or 
pharmacological drugs (Ferrer and Javitch, 1998; Chen et al., 2000).  Hydrophobic and charged 
residues of TMDs have received much attention as these amino acids might play a role in 
interactions with the aromatic ring or amine group of DA.  An aspartic acid residue in the first 
TMD is necessary for substrate recognition, thought to work through interactions of the carboxy 
group of aspartic acid and the positive charge of DA’s amino group (Torres et al., 2003).  These 
NSS transporters function using the sodium ion gradient generated by the plasma membrane 
protein Na+/K+ ATPase (reviewed by Torres et al., 2003), between the plasma membrane along 
with co-transport of chloride ions to translocate substrates transporters.  DAT specifically 
requires two sodium ions outside the cell and one chloride ion to transport a DA substrate, while 
the rest of SLC6 transporters need only one of each ion (reviewed by Torres et al., 2003).  
 
DAT Regulation 
 In addition to the aforementioned DAT oligomerization, the transporter is also subject to 
dynamic regulation mediated by post-translational modifications and protein-protein interactions.  
DAT substrates such as amphetamine and DA are capable of regulating surface levels and 
directing DAT internalization, while inhibitors like cocaine increase DAT surface levels 
(Saunders et al., 2000; Chi and Reith, 2003).  One of the most studied post-translational 
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modifications with respect to all monoamine transporters is phosphorylation, which possesses the 
ability to alter the function of these transporters in a variety of methods (Torres et al., 2003).  
Activated protein kinase C (PKC) has some of the best documented effects on the 
downregulation of DAT activity, which operates by decreasing the surface expression levels of 
DAT (endocytosis) by the administration of the phorbol ester PMA (phorbol 12-myristate 13-
acetate) (Zhu et al., 1997; Daniels and Amara, 1999; Melikian and Buckley, 1999; Chi and Reith, 
2003).  PKC, as proposed by Foster et al. (2002), primarily phosphorylates at a cluster of serine 
residues located at the N terminus of DAT.  It is important to note that truncation of these sites 
on DAT have shown that phosphorylation by PKC is not directly coupled to PMA-induced 
internalization (Granas, et al., 2003).   Ubiquitination, a common modification for regulating 
protein homeostasis (Raiborg and Stenmark, 2009), is another important post-translational 
modification that has been proposed to be involved in PKC-activated downregulation (Miranda 
et al 2007).  DAT is constitutively ubiquitinated at three lysines at its N-terminus, and 
introduction of PMA increases the frequency of ubiquitination.  Miranda et al (2007) showed 
these lysines were pivotal in ubiquitination of DAT when mutation of the trio to arginines 
stopped constitutive ubiquitination and PMA-stimulated downregulation, as a result of 
modification by the E3 ubiquitin ligase NEDD4-2 (Neuronal precursor cell expressed, 
developmentally down-regulated 4-2).  In another study by Miranda et al. (2005), ubiquitination 
was found to be prevalent in endosomes by fluorescence resonance energy transfer (FRET) 
experiments, pointing to the idea that ubiquitination could be an endocytic signal.  Holten et al. 
(2005) elucidated an internalization motif on the C terminus of DAT, a 10 residue sequence 
(FREKLAYAIA) that regulates constitutive and PKC-regulated DAT internalization.  A basal 
level of DAT trafficking between intracellular endosomal vesicles and the surface has been 
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measured at an endocytic rate of 3-5% of DAT surface levels per minute in PC12 cells (Loder 
and Melikian, 2003), this rate will vary in different cell.  PKC-mediated DAT sequestration was 
defined by Loder and Melikian (2003) as increasing basal DAT endocytic rates and slowing 
DAT cell-surface delivery.  Through the interleukin2-alpha receptor (Tac) chimeras with DAT, 
certain parts of the FREKLAYAIA internalization motif were discovered to have different roles.  
The distal five carboxy residues (AYAIA) were revealed to contain information required for 
constitutive DAT internalization, especially the nonpolar residues within this region as mutations 
to alanines resulted in a significant reduction in endocytic rates (Holten et al., 2005).  
FREKLAYAIA was shown to be well conserved among the SLC6 family members, as 
mutagenesis experiments with the cognate region in the norepinephrine transporter (NET) 
yielded a similar drop in endocytic rates (Holten et al., 2005).  In addition to a constitutive DAT 
internalization signal, the first five residues of FREKLAYAIA contain an independent and 
distinct signal for PKC-mediated DAT sequestration.  Point mutation disrupting basal DAT 
internalization did not yield any effect on PKC-stimulated DAT internalization, confirming the 
idea of independent and distinct signals on the FREKLAYAIA motif (Holten et al., 2005).  
 
DAT Protein Interactions 
Besides DAT regulation by post-translational modifications, protein to protein 
interactions have been postulated to regulate monoamine transporters based on two observations: 
monoamine transporters undergo trafficking in cells with the help of interacting proteins, and 
monoamine transporters are driven to specific locations on the presynaptic sites of nerve 
terminals under the direction of intracellular proteins (Torres et al., 2003).  One of the proteins 
that plays a role in DAT trafficking is a member of the Rit subfamily of Ras-like small GTPases, 
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Rin (Ras-like protein in neurons) or also termed Rit2 (Melikian et al., 2011).  Ras-related 
GTPases are molecular switches that, based on external signals, swap GTP for bound GDP.  
These GTP-bound active proteins interaction with a multitude of target effector proteins turning 
on intracellular signaling cascades (Campbell et al., 1998; Takai et al., 2001).   Rin is expressed 
in high concentrations, particularly in neuronal cells (Zhou et al., 2011), and is expressed in non-
neuronal cell lines like rat muscle and liver cells, primary cultured rat astrocytes, and mouse 
embryonic kidney cells (Melikian et al., 2011).  Specific co-localization was observed with DAT 
and Rin (using FRET microscopy) at specific focal points in the plasma membrane (Melikian et 
al., 2011).  These co-localization points were shown to be significantly higher at lipid raft 
microdomains within the plasma membrane than non-lipid raft microdomains (Melikian et al., 
2011).  Rin is required for PKC-mediated DAT trafficking, as shown by Melikian et al. (2011) 
by using reversible biotinylation to measure DAT internalization rates with co-expression of 
DAT and Rin mutants.  In addition, shRNA-mediated Rin knockdown showed that Rin is 
required for PKC-mediated DAT internalization.  Since Rin is required for PKC-mediated DAT 
trafficking, it is required to down-regulate the functional uptake of DA through DAT via 
administration of PMA (Melikian et al., 2011).  Rin dissociates from DAT based on the guanyl 
nucleotide exchange, as revealed from cellular imaging and co-immunoprecipitation experiments 
of Rin binding with the DAT C terminus (Melikian et al., 2011).  Additional results from 
Melikian et al. (2011) suggest a negative regulatory mechanism controlling DAT endocytic rates 
in residues 587-590 (REK), and that PKC activation regulates DAT/Rin interactions.  An 
endocytic brake has been proposed to exist here that slows DAT endocytic rates under normal 
conditions, yet is released during PKC activation (Boundanova et al., 2008) or mutations of 
residues (REK) 587-590 (Melikian et al., 2011).  Since Rin also binds with the C terminus, it has 
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been suggested that Rin provides a synergistic interaction between DAT’s C and N termini, 
regulating DAT’s endocytic rate (Melikian et al., 2011).  Recent evidence from Heo et al. (2006) 
outlines a polybasic charged domain conserved at the C terminus that facilitates Rin’s 
association with the plasma membrane, as the C-terminus lacks a prenylation box (CaaX) which 
distinguishes this protein from others in its Ras-like GTPase family.  This polybasic region of 
Rin also serves as a calmodulin (CaM) binding site (Lee et al., 1996) and has been shown to bind 
in vitro with CaM with the possibility of being regulated by Ca2+ levels in vivo (Lee et al., 1996; 
Hosino and Nakamura, 2003).  Hoshino and Nakamura have also shown CaM association to be 
necessary for Rin function.  Thus, a question remaining is whether calmodulin function upstream 
of Rin activation plays a role in PKC-stimulated DAT trafficking and regulation. 
 
Calmodulin 
 Calmodulin (CaM) is a ubiquitously expressed intracellular protein that is an important 
sensor of Ca2+ levels resulting in the regulation of a diverse group of intracellular proteins 
(Hoshino and Nakamura, 2003; Holten et al., 2005).  Interaction of CaM with these proteins is 
dependent on the intracellular levels of Ca2+ ions which bind CaM.  Protein kinases, cyclic 
nucleotides, cytoskeleton proteins, and ion channels are subjected to CaM regulation through 
varying Ca2+ levels.  This allows CaM to regulate cellular processes such as cell growth, 
proliferation, movement, and sensory transduction (Beckingham et al., 1998; Chin and Means, 
2000).  One of CaM’s most important roles in neurons and their targeted muscles is synaptic 
development and transmission, neuronal survival, and axonal outgrowth and path direction 
(Burgoyne and Weiss, 2001).  This multitude of important roles that CaM plays in neurons and 
other cells led to the identification of RIC (Ras-related protein which interacts with calmodulin, a 
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Drosophila homologue of Rin) as a potentially important compound in the development of 
neurons and sensory signaling (Wes et al., 1996).  RIC, one of the few proteins detected to 
interact directly with CaM, was the stepping stone to discovering a functional similarity in Rin 
(Harrison et al., 2005).  CaM was shown to inhibit the function of RIC in Drosophila, paralleling 
another small GTPase named Gem, which was reported as also being negatively regulated by 
CaM (Fischer et al., 1996).  CaM association with Gem displayed inhibited GTP binding 
(Fischer et al., 1996) and also disturbed association of Gem with downstream effector proteins 
preventing Gem function (Beguin et al., 2001).  These are functions of other small GTPase 
proteins that are related to or homologous with Rin. 
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Project Purpose 
 
The purpose of this project was to investigate whether CaM is required for the PKC-
stimulated decrease in DAT surface expression.  Through a protein signaling pathway, PKC 
activation from the phorbol ester PMA inhibits CaM function effectively releasing Rin and 
allowing for Rin-DAT interactions stimulating the internalization of DAT.  Since CaM is a 
negatively regulating protein involved in this signaling pathway, the role of CaM on DAT 
function was explored using the CaM inhibitor CGS 9343B in SK-N-MC cells stably expressing 
DAT.  Although the data acquired was not statistically significant, high doses above 1 μM 
appeared to decrease DAT uptake, while low concentrations CGS 9343B showed an increased 
specific uptake of DA (0.1 µM-10 µM).  This can either be a result of two processes: an increase 
of DAT function by causing it to function more efficiently thus increasing DA uptake, or by 
increasing the amount of DAT that is present on the cell surface.  To distinguish between these 
two possibilities, further biotinylation experiments will elucidate whether DAT SK-N-MC cells 
under certain CGS 9343B concentrations cause a difference in DAT cell surface expression 
levels.  In order to test whether the CaM inhibitor CGS 9343B could block PKC-induced DAT 
functional loss, DAT SK-N-MC cells were pre-treated with various doses of CGS before 
activating PKC using the phorbol ester PMA. This data was also not significant, but it will be 
interesting to see if the CaM inhibitor can block the PMA effect at low concentrations.  
Understanding these DAT trafficking molecular mechanisms can provide information into DA 
dysregulation and psychostimulant addiction, and may shed light on future therapeutic treatments 
for disorders pertaining to DAT. 
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Methods 
 
Cell Culture Techniques. Stably transfected SK-N-MC cells expressing wild-type DAT were 
maintained at 37oC, 5% CO2 in MEM supplemented with 10% fetal bovine serum, 2 mM 
glutamine, 102 U/mL penicillin/streptomycin, and under selective pressure from 0.2 mg/mL 
G418 (Invitrogen). 
 
[3H]-DA Uptake Assays.  Stable DAT SK-N-MC cells were plated on Falcon Multiwell 24-well 
polystyrene, non-pyrogenic plates at densities of 2x105 cells/well 24 hours prior to the 
experiment being conducted.  Indicated drugs were prepared just before the start of the uptake 
assay, where the cells in 24-well plates were washed twice at room temperature in KRH buffer 
(120 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 1.2 mM KH2PO4, 2.2 mM CaCl2, 10 mM 
HEPES, pH 7.4) and then pre-incubated in KRH buffer along with specified drugs for 60 
minutes (DMI = desipramine, to block uptake of DA by endogenously expressed NET) 
(GBR12909 = Vanoxerine, defines nonspecific uptake acting as a dopamine reuptake inhibitor 
“DRI”) (1µM PMA added at 30 minutes pending assay).  Dopamine uptake commenced with the 
addition of 1 µM [3H]-DA (3,4-[ring-2,5,6,-3H]DA, Perkin Elmer) in the presence of 10-5M 
pargyline and ascorbic acid.  Uptake proceeded for 10 minutes at 37oC, which was halted by 
washing three times with ice cold KRH buffer.  250 µL of scintillation fluid was added to each 
well to solubilize cells, and plates were shaken for 15 minutes.  The radioactivity levels of each 
well were measured by liquid scintillation counting using a Wallac Microbeta scintillation plate 
counter.  Microsoft Excel and GraphPad Prism Software were used to conduct the data analysis, 
including ANOVA and unpaired T tests.  
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Results 
 
The purpose of this project was to investigate whether calmodulin (CaM) is required for 
PKC-mediated down-regulation of DAT surface expression.  To test the possibility of CaM’s 
effect on DAT function, SK-N-MC cells stably expressing DAT were used in DA uptake assays 
to generate a dose-response curve using the CaM inhibitor CGS 9343B.  Initially, CGS 9343B 
was used at a range of 0.1 µM-10 µM, which was established using the IC50 of 3.3 µM reported 
by Norman et al. (1987).  Pre-treatment with CGS 9343B for 60 minutes at 37°C resulted in a 
dose dependent loss in DA uptake with an IC50 of 10.39 µM (Figure-1).  Visible is a downward 
trend of specific DA uptake starting after 1 µM.  The dose-response curve shows documented 
effects of CGS 9343B at reported selective CaM inhibiting concentrations. 
   
 
 
Figure 1: High Doses of CaM Inhibitor CGS 9343B Decreases DAT 
Function.  DA uptake assay was performed in presence of CaM inhibitor CGS 
9343B at various concentrations.  Average data was fit using log (inhibitor) vs. 
normalized data best fit line.  IC50 = 10.39 µM, n=2-3. 
  
Additional DA uptake assays were conducted using concentrations in a lower range (data 
not shown).  The first CGS 9343B dose response DA uptake assay [0.6 nM-30 nM] yielded an 
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increased specific DA uptake compared to that of the first tested range [0.1 µM-10 µM].  Seeing 
this unexpected increase in DA uptake led to further investigating the effects of CGS 9343B at a 
lower concentration range of 3 nM-100 nM (Figure-2).  CGS 9343B at 0.6 nM provided little 
effect on specific DA uptake, giving a good baseline for increasing concentrations above that 
level to show potential deviations from 100% uptake (horizontal dotted line, Fig. 2).  The trend 
continues upwards over the CGS 9343B range and begins to decrease after the peak at 60 nM.  
The most effective increase in specific DA uptake was at a concentration of 60 nM while the 
second most effective was at 300 nM.  This finding provided two good concentrations to use in 
conjunction with PMA to further test whether CGS 9343B could block PMA-induced DAT 
down-regulation. 
 
Figure 2: Low Doses of Drug CGS 9343B Increase DAT Function. n=1-7. 
 
 
In order to further explore whether CGS 9343B could block the effects of PMA-induced 
DAT function down-regulation, a DA uptake assay was conducted involving the addition of CGS 
at 60 nM and 300 nM with or without 1 µM of PMA (Figure-3).  Treatment with PMA gave 
about a 22% decrease in specific DA uptake compared to vehicle conditions.  As opposed to the 
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results from Figure 2, this experiment shows pretreatment of 300 nM of CGS yields the highest 
increase in specific DA uptake, a 14% increase over the vehicle, with 60 nM of CGS only having 
a 6% increase.  The magnitudes of the PMA effect on vehicle and 300 nM CGS pretreatment are 
quantified in Figure 4.  Unfortunately the experiment has not been completed enough times in 
order to show statistical significance between all of the treatments.  This leaves an opportunity to 
continue these DA uptake assays in the future to hopefully show a significant effect between the 
conditions of CGS ± PMA.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Summary of Various Treatments on DA Uptake.  PMA appears to 
lower DA uptake as expected, while CGS 9343B+PMA enlarges the decrease in 
specific uptake in DAT.  n=3-5.  
 
 
 Further expanding the results from Figure 3, the magnitude of the PMA effect was 
calculated between vehicle vs. PMA, and 300 nM CGS vs. 300 nM CGS/PMA (Figure 4).  PMA 
decreases DAT function relative to vehicle conditions or to pre-incubated cells with 300 nM 
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CGS 9343B.  The magnitude of the PMA effect when pretreated with CGS is about 10% higher 
than without CGS (vehicle vs. PMA). 
 
 
 
 
 
 
 
 
 
 
Figure 4: Pre-incubation with 300 nM CGS Increases the Magnitude of 
PMA-Induced Down-Regulation of DAT Function.  n=4 
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Discussion 
   
This project sought to determine whether calmodulin (CaM) is required in the signaling 
pathway of PKC-induced DAT downregulation.  DAT function was assayed using a [3H]-DA 
uptake assay.  The main experiment conducted was a DA uptake assay under two different 
parameters: a dose-response using varying concentrations of CaM-inhibitor CGS 9343B on DAT 
function, and the effect of CGS 9343B at two different concentrations with or without PMA, to 
test whether CGS can block a PMA-induced DAT downregulation.  Figure 1 shows the effects of 
CGS 9343B on DAT-stable SK-N-MC cells using a concentration range of 0.1 µM-10 µM.  A 
best fit log of inhibitor line was generated using the analyze function of the GraphPad Prism 
program yielding an experimentally calculated IC50 of 10.89 µM.  Comparing this with the 
reported IC50 of CGS 9343B is 3.3 µM (Norman et al., 1987) reaffirms the fact that this CGS 
9343B dose response DA uptake assay was not performed enough times, otherwise the 
experimentally calculated IC50 value would have approached its reported value.  It is important 
to note that another lab has demonstrated that CGS 9343B is not entirely specific for CaM in 
concentrations that were used for this uptake assay.  Neuhaus & Reber (1992) showed that CGS 
9343B inhibits current amplitudes at a concentration of 3.0 µM, and is reversible when washed at 
a concentration of 10 µM.  CGS also blocks the transient increase of Ca2+ during depolarization 
at a concentration of 10 µM, and after a five minute incubation it completely blocked this.  At 10 
µM, CGS also causes a reversible inhibition of K+ and Na+ voltage-gated channels.  The authors 
made a point to stress that the rapid reversibility of blocking currents argues against CGS’s 
involvement in the Ca2+ and CaM complex (Neuhaus and Reber, 1992). These initial Figure-1 
experiments were a good introduction to the lab, and they also served to show the inhibitory 
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effects of CGS 9343B on CaM activity, and its downregulating effect on the function of DAT’s 
specific DA uptake.   
The next experiment was a dose response of CGS 9343B, but using lower concentrations 
ranging from 0.6 nM-300 nM.  The horizontal line shows where basal levels of DA uptake are 
(100%), and all the concentrations at this range are above this level.  CGS, for some reason, in 
this range appears to cause an increased amount of specific DA uptake.  60 nM has the highest 
specific DA uptake at 128.0±9.2% (n=6) and 300 nM has the second highest at 121.2±5.3% 
(n=2).  These two values are especially important because according to Figure 2 they have the 
biggest increase in DAT function which gives them credibility to use in other experiments 
assessing CGS 9343B regarding DAT function.  These results potentially showing elevated 
levels of DAT function says two things: 1) that CGS in this concentration range may increase the 
function of DAT by causing more DA to be taken up into the cell, or that 2) CGS is causing the 
level of DAT surface expression to increase allowing more DATs to bring in more DA.  Since 
CGS 9343B is generally not used at this low of concentrations, it is interesting that these effects 
are occurring.  What CGS is actually doing is unknown, and is an area that will be explored next 
using surface biotinylations of SK-N-MC cells to quantify the surface levels of DAT.  This 
experiment will allow us to determine how much DAT is on the surface of these cells under: 
basal conditions, PMA, CGS, and PMA/CGS pretreatments.  Once the levels of DAT surface 
expression are calculated from these experiments, it will answer the question whether CGS in 
this concentration range causes an increase of DAT surface expression.  Using these results in 
conjunction with the DA uptake assay, a CGS 9343B dose response will start to elucidate the 
effect that CGS is having on DAT in SK-N-MC cells.   
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The last DA uptake assay conducted for this project tested the effects of pre-incubated 
CGS (at 60 nM and 300 nM) in conjunction with PMA incubation for 30 minutes.  A 30 minute 
PMA incubation yielded a 22.1±2.9% decrease in specific DA uptake, but has increased effects 
when combined with CGS pretreated cells.  300 nM of CGS had the highest average specific DA 
uptake (note it is not consistent with data from Figure 2 where 60 nM has the highest average 
specific DA uptake) of 114±6.5% while 60 nM had an uptake of 106.5±10.3%.  CGS at 300 nM 
also had the largest average magnitude of the PMA effect (Fig. 4) at a difference of 32.9±3.5%.  
Due to the low number of experiments conducted (n-value ranging from 3 to 5), the only pair of 
treatments that were shown to be significant (data not shown) were 300 nM CGS vs 300 nM 
CGS/PMA.  More experiments will need to be conducted to show statistical significance 
according to ANOVA using Šídák’s multiple comparisons tests among the other desired pairs 
(vehicle vs. 300 nM CGS or 60 nM CGS; 60 nM CGS vs. 60 nM CGS/PMA).  Additionally, 
Figure 4 quantifies the magnitude of the PMA effect between vehicle conditions and 
pretreatment with 300 nM CGS.  According to an unpaired T test (results not shown), the two 
magnitudes are not significantly different (n = 4).  Conducting more of the aforementioned CGS 
and PMA DA uptake assays will generate more data to conclude whether or not the difference in 
PKC-stimulated decrease in DAT function is significant.  If it is, this will show that PMA’s DAT 
down-regulating effects combined with CGS’ functional increase in DA uptake are causing an 
increased magnitude of PMA-induced decrease in DA uptake.  We speculate that this could 
mean CGS 9343B possesses the capability to increase PMA’s effect on DAT function, allowing 
it have an increased magnitude of decreased specific DA uptake.  Since CGS 9343B acts through 
the inhibition of the CaM-stimulated cAMP phosphodiesterase (PDE1) to inhibit CaM (Norman 
et al., 1987), it is possible that removing CaM’s inhibitory effect on Rin with CGS 9343B allows 
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the protein pathway that contains protein kinase C (PKC) to also inhibit CaM, thus allowing an 
even larger PMA-induced downregulation of DAT surface expression.  Since CaM interacts with 
Rin in order to negatively regulate DAT trafficking through inhibition of Rin, the increased PMA 
effect could potentially inhibit more CaM in conjunction with CGS 9343B leading to more DAT-
Rin interactions, effectively internalizing more DAT. This would mean that the same 
concentration of PMA (1 µM) is causing more DAT to be internalized, leading to the increased 
magnitude of DAT decrease in specific DA uptake seen in Figure 4.  Although these are just 
speculations, repeating these experiments, in addition to conducting surface biotinylations, will 
start to give an answer to the question of whether CaM is required for PKC-induced DAT surface 
loss.  It will also shed light on possible mechanisms for how CGS 9343B at low concentrations is 
increasing DAT function.  All of this information is relevant to revealing the protein cascade 
pathways that orchestrate DAT internalization from varying signal pathways.   
The importance of these conclusions could be applied to discoveries of therapeutic 
treatments for disorders pertaining to DAT dysfunction and an increased understanding of 
psychostimulant addiction and overall knowledge of the DAT and its regulatory mechanisms. 
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